-
ASH 2024 | Dr. Huafeng Wang’s Team Shines with Four Groundbreaking Studies on MDS Therapies and AML Innovations
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7 to 10, 2024, in San Diego, USA. Renowned as the largest international academic event in hematology, the conference showcased cutting-edge research and the latest advancements in drug development, representing the highest academic standards in the field. At this prestigious…
-
AASLD Exclusive Interview with Dr. Grace Lai-Hung Wong: Quantitative HBsAg – A New Perspective in Advancing Hepatitis B Management and Functional Cure
Understanding the Significance of Quantitative HBsAg Hepatology Digest: In your presentation, you discussed the quantification of HBsAg. How does it contribute to understanding HBV infection and disease progression? Dr. Grace…
-
ASH 2024 | Dr. Erlie Jiang: Elevated rhTPO Dosing Accelerates Platelet Engraftment and Reduces aGVHD in Allo-HSCT
The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay…
-
ASH 2024 | Dr. Mingfeng Zhao: Pursuing Innovation—iCAR-T Therapy Offers New Hope for AML Treatment
Acute myeloid leukemia (AML) remains a major clinical challenge due to its high heterogeneity. While CAR-T cell therapy has shown tremendous success in treating various hematologic malignancies, its application in AML is still in its infancy, necessitating further research and exploration. At the 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7–10,…
-
ASH 2024 | Dr. Wenbin Qian: In-Depth Analysis of Three Key Advances in CAR-T Cell Therapy for Lymphoma
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. Among the highlights of this year’s conference were three oral presentations (Oral 94,…
-
ASH 2024 | Dr. Peihua Lu: Promising Efficacy and Controllable Safety of CD7 CAR-T Cell Therapy in Treating R/R PTCL
The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10, 2024, in San Diego, showcased cutting-edge advancements in hematology. Among the highlights was a study led by Dr. Peihua Lu from the Beijing Lu Daopei Hematology Hospital, presenting Phase I clinical trial results on CD7 CAR-T cell therapy for relapsed…
-
ASH 2024 | Dr. Sizhou Feng: Improved Preconditioning Regimens and Novel Maintenance Therapies Bring New Momentum to Leukemia Transplantation
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, bringing together global experts and scholars in hematology for an in-depth exploration and exchange of the latest research progress in the field. At this conference, two studies by Dr. Sizhou Feng’s team from the Institute…
-
AASLD Exclusive Interview with Dr. Vincent Wai-Sun Wong: Challenges and Frontiers in Managing MASLD in Asia
Epidemiological Characteristics of MASLD in Asia Hepatology Digest: Could you elaborate on the epidemiological characteristics of MASLD in Asia? How does it differ from other regions? Dr. Vincent Wai-Sun Wong:…
Connecting Medical Expertise through Media